Search





Search





Markets
/
Stocks
/
nasdaq-gkos
/

Glaukos Corp

GKOS

Add to Watchlist

137.230USD

+0.870+0.64%

Close 05/13, 16:00（ET）Quotes delayed by 15 min

7.89BMarket Cap

LossP/E TTM



Glaukos Corp

137.230

+0.870+0.64%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Glaukos Corp

Currency: USD Updated: 2026-05-12

Key Insights

Glaukos Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 13 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 151.92.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Glaukos Corp's Score

Industry at a Glance

Industry Ranking

13 / 206

Overall Ranking

86 / 4490

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Glaukos Corp Highlights

StrengthsRisks

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 61.24% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 507.44M.

Fairly Valued

The company’s latest PE is -41.29, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 59.35M shares, decreasing 4.48% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 295.00 shares of this stock.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

151.917

Target Price

+13.78%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-12

The current financial score of Glaukos Corp is 7.02, ranking 93 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 150.57M, representing a year-over-year increase of 41.16%, while its net profit experienced a year-over-year increase of 9.02%.

Score

Industry at a Glance

Previous score

7.02

Change



Financials

7.86

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.33

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.09

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.71

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.13

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Glaukos Corp's Company Valuation

Currency: USD Updated: 2026-05-12

The current valuation score of Glaukos Corp is 7.24, ranking 106 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -41.29, which is -62.42% below the recent high of -15.52 and -97.50% above the recent low of -81.55.

Score

Industry at a Glance

Previous score

7.24

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 13/206

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-12

The current earnings forecast score of Glaukos Corp is 8.38, ranking 45 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 120.00, with a high of 165.00 and a low of 72.00.

Score

Industry at a Glance

Previous score

8.38

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

151.917

Target Price

+12.22%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

116

Total

Median

Average

Company name

Ratings

Analysts

Glaukos Corp

GKOS

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-12

The current price momentum score of Glaukos Corp is 9.23, ranking 19 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 151.07 and the support level at 117.32, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.15

Change

0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.636

Buy

RSI(14)

63.272

Neutral

STOCH(KDJ)(9,3,3)

51.087

Sell

ATR(14)

6.735

High Vlolatility

CCI(14)

46.188

Neutral

Williams %R

30.785

Buy

TRIX(12,20)

0.732

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

134.934

Buy

MA10

134.479

Buy

MA20

128.228

Buy

MA50

116.584

Buy

MA100

116.316

Buy

MA200

103.342

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-12

The current institutional shareholding score of Glaukos Corp is 10.00, ranking 1 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 101.04%, representing a quarter-over-quarter decrease of 0.52%. The largest institutional shareholder is PRIMECAP Management, holding a total of 3.38M shares, representing 5.75% of shares outstanding, with 169.63% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

8.07M

+3.43%

PRIMECAP Management Company

Star Investors

3.38M

+49.83%

Janus Henderson Investors

3.02M

+183.40%

State Street Investment Management (US)

2.12M

+0.86%

Burns (Thomas William)

1.62M

+0.73%

AllianceBernstein L.P.

1.64M

-5.19%

Millennium Management LLC

1.61M

+76.23%

Geode Capital Management, L.L.C.

1.32M

+0.12%

Risk Assessment

Currency: USD Updated: 2026-05-12

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Glaukos Corp is 5.96, ranking 68 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.94. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.